Skip to main content
Delfa

← All trials/NCT07340788

Not yet recruitingPhase NA

Amylin-Induced Migraine Attacks Without Aura

Amylin-Induced Migraine Attacks Without Aura: A Randomized Clinical Trial

Asset

Pramlintide

Amylin analog

Listed sites

1

Recruiting sites

-

Estimated enrollment

21

Study population

Headache Disorders

Eligibility highlights

-

Primary endpoint

•Migraine attacks without aura

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07340788
Org study IDH-24025082

Timeline

Milestones

Study first posted2026-01-14actual
Last update posted2026-01-14actual
Primary completion2028-10-30estimated
Study completion2028-10-30estimated
Study start2026-02estimated (month precision)

Assets

Investigational agents

Pramlintide

Who this study enrolls

Headache Disorders

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Age 18 to 65 years of age upon entry into screening
•A body weight of 50 to 100 kg
•History of migraine without aura for ≥12 months and in accordance with ICHD-3
•Between 1-5 monthly migraine days without aura on average across the 3 months prior to screening
•Provision of informed consent prior to initiation of any study-specific activities/procedures

Exclusion criteria

•Any history of a primary or secondary headache disorder other than migraine without aura and infrequent episodic tension-type headache
•Any history of moderate to severe traumatic brain injury
•Any history of cardiovascular disease, including cerebrovascular diseases
•Any history of pulmonary disease
•Any other clinically significant disorders, conditions, or diseases that might impact the safety of the subject or interfere with the study's evaluation, procedures, or completion, aside from those mentioned above. This includes any relevant medical history or evidence that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results
•The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior
•Female subjects of childbearing potential with a positive pregnancy test during any study visit
•Cardiovascular disease of any kind, including cerebrovascular diseases
•Hypertension (systolic blood pressure of ≥150 mmHg and/or diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day
•Hypotension (systolic blood pressure of ≤90 mmHg and/or diastolic blood pressure of ≤50 mmHg)
•Abnormalities on the electrocardiogram that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results
•Daily use of any medication other than contraceptives
•Intake of any medication other than contraceptives within 48 hours of infusion start
•Intake of caffeine, nicotine, and alcohol within 12 hours of infusion start
•Headache of any intensity within 48 hours of infusion start
•Migraine attack within 48 hours of infusion start
•Aura within 48 hours of infusion start

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers
2
Other clinical outcomes
2

Cardiometabolic biomarkers

2 endpoints
Other/protocol endpoint/low confidence

Superficial temporal artery dilation

Time frame:2 hours

descriptive

Other/protocol endpoint/low confidence

Middle cerebral artery blood flow velocity

Time frame:2 hours

descriptive

Other clinical outcomes

2 endpoints
Primary/protocol endpoint

Incidence of migraine attacks without aura

Time frame:12 hours

event count, event

Secondary/protocol endpoint

Headache intensity scores

Time frame:12 hours

descriptive, improvement

Publications (8)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.